Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Pediatric 6 to 11 Years Old Study)

X
Trial Profile

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Pediatric 6 to 11 Years Old Study)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms PROMISE Pediatric
  • Most Recent Events

    • 21 Jun 2023 New trial record
    • 09 May 2023 Preliminary results (n=70) assessing fecal microbiota changes in cystic fibrosis children treated with Elexacaftor/Tezacaftor/Ivacaftor, presented at the Digestive Disease Week 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top